AbbVie signed on to buy rival drugmaker Allergan for $63 billion.
The bid values Allergan's shares at a 45% premium.
The acquisition would combine AbbVie, the maker of arthritis drug Humira, and Allergan, which is known for its wrinkle treatment Botox, among other products.
Read more from Bloomberg.
Developers say city needs a variety of housing types to meet demand.